RESUMEN
AIMS: Recent reports in the literature have suggested that glucagon-like peptide-1 (GLP-1)-based therapies may lead to increased risk of pancreatic pathology leading to chronic pancreatic injury and pancreatic neoplasia. Extensive non-clinical and clinical safety testing was conducted to support the global development of exenatide twice daily, exenatide once weekly and saxagliptin. Our aim was to integrate these non-clinical data obtained with both mechanisms of GLP-1-based drugs to provide complementary data regarding the potential for drug-induced pancreatic safety signals. METHODS: More than 70 regulated non-clinical toxicology studies in rodents and non-rodents were conducted in accordance with International Conference on Harmonisation and US Food and Drug Administration guidance documents, current industry standards, animal welfare regulations and in compliance with Good Laboratory Practice regulations. Treatment duration was up to 2 years in rodents and up to 12 months in non-rodents using high doses representing large multiples of human exposures (up to 130× for exenatide and 2200× for saxagliptin). Comprehensive pancreas assessments involved more than 2400 pancreata from animals exposed to exenatide and over 1700 pancreata from animals exposed to saxagliptin. RESULTS: Neither exenatide nor saxagliptin treatment resulted in drug-related microscopic changes indicative of acute or chronic adverse effects (including neoplasia) in the endocrine or exocrine pancreas, at doses far exceeding the maximum human systemic exposures. CONCLUSIONS: These data substantially add to the weight of evidence supporting the lack of non-clinical drug-induced pancreatic safety signals in animals exposed to GLP-1-based therapies.
Asunto(s)
Adamantano/análogos & derivados , Diabetes Mellitus Experimental/tratamiento farmacológico , Dipéptidos/farmacología , Péptido 1 Similar al Glucagón/agonistas , Páncreas/patología , Péptidos/farmacología , Ponzoñas/farmacología , Adamantano/farmacología , Animales , Perros , Exenatida , Haplorrinos , Inyecciones Subcutáneas , Dosis Máxima Tolerada , Ratones , Tamaño de los Órganos , Páncreas/efectos de los fármacos , RatasRESUMEN
CI-994 (acetyldinaline) is an investigative oral anticancer drug currently in clinical trials. To characterize the effects of CI-994 on lymphoid tissue, male rats were administered single oral doses at 0 (vehicle control), 10, 23, and 45 mg/kg and killed up to 7 days after dosing for evaluation of white blood cell differentials, bone marrow differentials, lymphoid tissue weights, and selected histopathology of lymphoid tissue. Statistically significant dose-related reductions in blood lymphocytes (CD-3+, CD-4+, CD-8+, CD-20+), monocytes, neutrophils, and bone marrow lymphoid cells were observed in all drug-treated groups on days 1 and/or 3. Statistically significant reductions in bone marrow myeloid cells were also observed on days 1 and 3 at 23 and 45 mg/kg. Complete or partial reversal of most parameters was evident on day 7. Spleen and/or thymus weights were significantly decreased in the groups administered 23 and 45 mg/kg on days 1, 3, and/or 7. Minor reductions in lymphoid organ weights were noted at 10 mg/kg. Minimal to moderate lymphoid depletion of the spleen and thymus was noted on day 3 in animals dosed at 23 mg/kg. In vitro, CI-994 inhibited mitogen-stimulated blood lymphocyte proliferation with a 50% inhibitory concentration (IC50) value of 3 microM. The results demonstrate that CI-994 can effect lymphoid tissue in rats within 1 day of a single oral dose, that effects are generally reversible within 7 days, and that inhibition of lymphocyte proliferation is a sensitive indicator of CI-994 immunotoxicity in vitro.
Asunto(s)
Antineoplásicos/toxicidad , Médula Ósea/efectos de los fármacos , Tejido Linfoide/efectos de los fármacos , Tamaño de los Órganos/efectos de los fármacos , Fenilendiaminas/toxicidad , Animales , Antineoplásicos/inmunología , Benzamidas , Biomarcadores , Recuento de Células Sanguíneas/efectos de los fármacos , División Celular/efectos de los fármacos , Concanavalina A/farmacología , Relación Dosis-Respuesta a Droga , Técnicas In Vitro , Leucocitos/efectos de los fármacos , Tejido Linfoide/inmunología , Tejido Linfoide/patología , Masculino , Fenilendiaminas/inmunología , Ratas , Ratas Wistar , Bazo/efectos de los fármacos , Bazo/patología , Timo/efectos de los fármacos , Timo/patología , Factores de TiempoRESUMEN
Diphenylhydantoic acid (DPHA) is a degradation product in parenteral formulations of the anticonvulsant phenytoin and the prodrug fosphenytoin. DPHA has also been reported to be a minor metabolite of phenytoin. Levels found in the urine of various species, including humans, after oral or intravenous (iv) phenytoin ranged from undetected to a few percent of administered dose. In the present analysis, the toxicologic profile of DPHA was integrated with exposure data in order to characterize its safety under recommended clinical regimens of fosphenytoin administration. In preclinical safety studies, DPHA was without effect in the Ames assay and at concentrations up to 3000 microg/plate in the presence or absence of metabolic activation, and in the in vitro micronucleus test with acute and 2-week repeated dose studies in Wistar rats at iv doses up to 15 mg/kg. In 4-week studies conducted in rats and dogs receiving fosphenytoin containing DPHA levels up to 1.1%, and in an in vitro structural chromosome aberration test with DPHA levels up to 2.0%, all findings were consistent with known effects of phenytoin (such as CNS signs and increased liver weight), and none were attributed to DPHA. Reports in the literature indicate that in murine in vivo and in vitro models, DPHA has much lower potential for reproductive toxicity than phenytoin. A no-observed-effect level (NOEL) of 15 mg/kg established from the 2-week study in rats was used with probabilistic techniques to estimate tolerable daily doses (TDDs) of DPHA. In this approach, interspecies correction was performed by allometrically scaling the NOEL based on a distributional power of body weight while intraindividual variability was accounted for by selecting the lower percentiles of the population-based distribution of TDDs. The results indicate that a DPHA content limit of 3.0% in an administered dose of fosphenytoin is unlikely to cause adverse effects in patients.
Asunto(s)
Anticonvulsivantes/química , Fenitoína/análogos & derivados , Fenitoína/química , Profármacos/química , Adolescente , Adulto , Anciano , Animales , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/metabolismo , Gatos , Perros , Relación Dosis-Respuesta a Droga , Contaminación de Medicamentos , Femenino , Haplorrinos , Humanos , Infusiones Parenterales , Masculino , Concentración Máxima Admisible , Ratones , Persona de Mediana Edad , Método de Montecarlo , Fenitoína/administración & dosificación , Fenitoína/metabolismo , Fenitoína/toxicidad , Profármacos/administración & dosificación , Profármacos/metabolismo , Ratas , Ratas WistarRESUMEN
The anti-cancer compound CI-1010, designated as (R)-alpha-([(2-bromoethyl)amino]methyl)-2-nitro-1H-imidazole-1-ethanol monohydrobromide, has a proposed dual mechanism of action due to alkylating and radiosensitizing activities. To assess potential toxicity, adult Wistar rats were treated with a single intravenous injection (0, 50, 100, 150, 225, or 350 mg/kg) and necropsied at 4 or 29 days following treatment. In a repeated dose experiment, rats were injected daily (0, 10, 40, or 80 mg/kg; 5 doses/wk) for 3 wk and necropsied at the end of week 3 or 7. CI-1010 induced retinal degeneration by 4 days after a single injection of > or = 225 mg/kg or by 3 wk of repeated injections of > or = 40 mg/kg. The locally extensive to diffuse retinal degeneration involved the photoreceptor and outer nuclear layer. The photoreceptor layer was vacuolated and compressed corresponding to ultrastructural evidence of inner segment swelling and outer segment fragmentation. The outer nuclear layer was thinned due to loss of nuclei and contained numerous pyknotic or karyorrhectic nuclei. These nuclear changes were morphologically consistent with apoptosis and many outer nuclear layer nuclei labeled with in situ TdT-mediated dUTP-digoxigenin nick end labeling (Apoptag). The retinal degeneration was nonreversible, evidenced by increased lesion severity and incidence after CI-1010 was withdrawn for either 25 or 28 days.
Asunto(s)
Ojo/efectos de los fármacos , Nitroimidazoles/toxicidad , Profármacos/toxicidad , Fármacos Sensibilizantes a Radiaciones/toxicidad , Degeneración Retiniana/inducido químicamente , Administración Tópica , Animales , Ojo/patología , Ojo/ultraestructura , Femenino , Masculino , Ratas , Ratas Wistar , Degeneración Retiniana/patologíaRESUMEN
CI-994 (acetyldinaline) is an orally active anticancer drug currently in Phase 1 clinical trials. To assess its preclinical toxicity, CI-994 was administered orally as suspensions to Wistar rats (10/sex/dose) and in capsules to beagle dogs (3/sex/dose) once daily for two weeks. Doses were 1.5, 5, and 15 mg/kg for rats (9, 30, and 90 mg/m2, respectively), and 0.5, 2, and 5 mg/kg for dogs (10, 40, and 100 mg/m2, respectively). Systemic exposure was dose-proportional based on toxicokinetic analysis in dogs. Severe clinical signs and mortality occurred at the highest dose in both species beginning on Day 10. Neutropenia, lymphocytopenia, thrombocytopenia, lymphoid depletion, bone marrow hypocellularity, and testicular degeneration were observed in both species, primarily at the mid- and high-doses. Despite continued treatment, neutrophil counts in dogs returned to control levels in Week 2. Other microscopic findings in rats included splenic hematopoietic depletion at all doses and epithelial cell necrosis in various tissues at 15 mg/kg. Additional bone marrow changes in dogs involved myeloid and megakaryocyte hyperplasia at 2 mg/kg and abnormal myeloid and megakaryocyte maturation at 2 and 5 mg/kg. Except for the testicular effects in both species, all changes were reversible within a 4-week (rat) or 9-week (dog) recovery period. The results of these studies show that target organ effects of CI-994 principally involve tissues with rapidly dividing cell populations and that bone marrow suppression is the dose-limiting toxicity. CI-994 also seems to interfere with the release and/or maturation of cells in the bone marrow.
Asunto(s)
Antineoplásicos/toxicidad , Fenilendiaminas/toxicidad , Animales , Antineoplásicos/administración & dosificación , Antineoplásicos/sangre , Benzamidas , Análisis Químico de la Sangre , Peso Corporal/efectos de los fármacos , Enfermedades de la Médula Ósea/inducido químicamente , Enfermedades de la Médula Ósea/patología , Perros , Ingestión de Alimentos/efectos de los fármacos , Femenino , Cinética , Recuento de Leucocitos/efectos de los fármacos , Masculino , Tamaño de los Órganos/efectos de los fármacos , Fenilendiaminas/administración & dosificación , Fenilendiaminas/sangre , Ratas , Ratas Wistar , Caracteres Sexuales , Testículo/patologíaRESUMEN
Amsacrine, a DNA intercalator and topoisomerase II inhibitor, is efficacious as an antileukemogenic agent. This study was conducted to assess the subchronic toxicity of amsacrine in rats following a cyclic clinical dosing regimen and as a range-finding experiment for a subsequent carcinogenicity bioassay. Groups of 30 male Wistar rats were administered drug intravenously at doses of 0, 0.25, 1.0, and 3.0 mg/kg daily for 5 days followed by 23 days without treatment. This cycle of dosing and recovery was repeated six times to simulate human clinical usage of the drug. Assessments of hematology, clinical chemistry, and gross and microscopic pathology were conducted 3 and 21 days following completion of dosing in the first, third, and sixth cycles. There were no deaths during the study. Hair loss, diarrhea, tail injuries, chromodacryorrhea, and rhinorrhea were observed primarily in animals administered 3 mg/kg. Hair loss and diarrhea occurred during periods of dosing and generally resolved during the recovery phase of each cycle. Both of these signs became progressively more severe during the latter half of the study. Body weight loss and reduced food consumption also occurred in the 3 mg/kg group during each week of dosing. At study termination, mean body weight and food consumption of the 3 mg/kg group were significantly less than those of controls by approximately 20 and 50%, respectively. Marked, reversible leukopenia associated with reductions in both neutrophil and lymphocyte counts occurred in cycles one and three in animals administered 1 and 3 mg/kg, respectively. Reversible neutropenia was also observed in the 3 mg/kg group in cycle 6. Similar effects on platelet counts were seen in the 3 mg/kg group in all three cycles analyzed. Absolute and relative testes weights of the 3 mg/kg group were significantly less than the vehicle controls at all time points in the third and sixth cycles. Relative testes weights were also decreased in the 1 mg/kg group in cycle 6. Reversible decreases in absolute relative spleen weights occurred in all drug-treated groups in cycle 1 and for the 3 mg/kg group in cycle 3. Lymphoid depletion (spleen, thymus, lymph node), marked hypocellularity of bone marrow, segmental degeneration of seminiferous tubules, and intestinal epithelial cell degeneration were observed at 3 mg/kg. With the exception of testicular changes which remained evident at the end of cycle 6, pathologic lesions were reversible during the 23-day recovery period of each cycle. The results show that the subchronic toxicity of amsacrine is consistent with a cytotoxic mechanism and that target organs are generally tissues with the highest rates of cell turnover. The doses administered in this study induced a range of effects which were minimal at 0.25 mg/kg and dose-limiting at 3 mg/kg and therefore were considered appropriate for use in the subsequent carcinogenicity bioassay.
Asunto(s)
Amsacrina/toxicidad , Antineoplásicos/toxicidad , Animales , Médula Ósea/efectos de los fármacos , Médula Ósea/patología , Evaluación Preclínica de Medicamentos , Inyecciones Intravenosas , Yeyuno/efectos de los fármacos , Yeyuno/patología , Recuento de Leucocitos , Masculino , Tamaño de los Órganos/efectos de los fármacos , Ratas , Ratas Wistar , Testículo/efectos de los fármacos , Testículo/patologíaRESUMEN
Amsacrine is an antineoplastic drug used in the treatment of acute adult leukemias. To assess its carcinogenic potential, groups of 50 male and 50 female rats were administered amsacrine by lateral tail vein injection at 0 (vehicle control), 0.25, 1, or 3 mg/kg once daily for 5 days, followed by a 23-day recovery period. This cycle of dosing and recovery was repeated a total of six times. The animals were then maintained without dosing for an 18-month observation period. During the dosing phase, signs of toxicity were limited to the 3 mg/kg animals and included alopecia, diarrhea, injection site lesions, and skin and subcutaneous nodules. Statistically significant reductions in body weight gain and food consumption also occurred at 3 mg/kg during each 5-day dosing period followed by recovery during the latter 3 weeks of each cycle. Except for skin and subcutaneous nodules, signs of toxicity in the 3 mg/kg animals ultimately disappeared during the 18-month observation phase. Survival at study termination for the vehicle control, 0.25, 1, and 3 mg/kg groups was 56, 52, 34, and 0%, respectively, in males, and 64, 48, 54, and 4%, respectively, in females. Mortality was primarily due to bone marrow suppression during the dosing phase, chronic progressive nephropathy, or development of tumors. Incidences of the following tumors were significantly increased in the 3 mg/kg groups of both sexes (Fisher exact test, two-tailed, p < 0.01): all malignancies; all tumors of the small intestine, adenocarcinoma and adenoma of the small intestine, all tumors of the skin, and squamous cell papilloma. Other tumor incidences that were significantly increased in the 3 mg/kg males were thymoma and multiple neoplastic histotypes of the skin and adnexa including basal cell tumor, fibroma, sebaceous gland adenoma, and squamous cell carcinoma. A disproportionate number of the skin tumors were located on the tail, suggesting a localized tissue concentration effect. In the 3 mg/kg females, significantly increased tumor incidences also included all tumors of the mammary gland, adenocarcinoma of the mammary gland, all tumors of the uterine horn, and endometrial stromal polyps of the uterine horn. The 1 mg/kg males had significantly increased incidences of all tumors of the small intestine and skin, adenocarcinoma of the small intestine, and fibroma of the skin. Fibroma of the skin was also significantly increased in the 0.25 mg/kg males. Incidences of all tumors and all benign tumors were significantly increased in the 1 mg/kg females. There were no significantly increased tumor incidences in the 0.25 mg/kg females. The results of this study show that amsacrine is carcinogenic in Wistar rats. Target organs for tumorigenicity include small intestine, skin, mammary gland, thymus, and uterus.
Asunto(s)
Amsacrina/toxicidad , Antineoplásicos/toxicidad , Carcinógenos/toxicidad , Animales , Pruebas de Carcinogenicidad , Evaluación Preclínica de Medicamentos , Femenino , Neoplasias Intestinales/inducido químicamente , Intestino Delgado/patología , Masculino , Neoplasias Mamarias Animales/inducido químicamente , Ratas , Ratas Wistar , Neoplasias Cutáneas/inducido químicamenteRESUMEN
Misonidazole is a hypoxic cell radiosensitizer that induces a peripheral neuropathy in humans after exceeding a schedule-dependent cumulative threshold dose. Clinical studies of misonidazole have been conducted using oral administration, whereas most other radiosensitizers have been administered intravenously. Since route of exposure can potentially influence the toxicity of xenobiotics, the objective of this study was to assess the neurotoxicity of misonidazole in rats following intravenous dosing using a battery of routine clinical, neurofunctional, biochemical, and histopathologic screening methods. Male Sprague-Dawley rats were administered intravenous doses of misonidazole at 0 (vehicle control), 100, 200, 300, or 400 mg kg-1 once per day, 5 days per week, for 2 weeks. Animals were evaluated for neurofunctional and pathological changes following termination of treatment (Days 15-17) and at the end of a 4 week observation period (Days 43-45). During the dosing phase, hypoactivity, salivation, rhinorrhea, chromodacryorrhea, rough pelage and ataxia were observed at 400 mg kg-1, and body weight gain of the 300 and 400 mg kg-1 groups was significantly decreased relative to the vehicle controls by 24% and 49%, respectively. Corresponding reductions in food consumption were 8% and 23%, respectively. Although most 400 mg kg-1 animals appeared normal on Day 15 prior to the neurofunctional evaluations, rotorod testing precipitated a number of clinical signs including: ataxia, impaired righting reflex, excessive rearing, tremors, vocalization, circling, head jerking, excessive sniffing and hyperactivity. All of these animals recovered and appeared normal from Day 17 through study termination. There were no treatment-related effects on motor activity, acoustic startle response, rotorod performance, forelimb group strength, toe and tail pinch reflexes, tibial nerve beta-glucuronidase activity or tail nerve conduction velocity. Although hindlimb grip strength of the 400 mg kg-1 group was significantly decreased by 17% relative to the vehicle controls on Day 15, this finding appeared related to the reduced food consumption and body weight gain in these animals. No microscopic changes were detected in peripheral nerves. Necrosis and proliferation of fibrillary astrocytes (gliosis) were seen in the cerebellum and medulla of the 400 mg kg-1 animals on Day 16. Gliosis in these same brain regions was observed in the 300 and 400 mg kg-1 groups on Day 44. The results show that intravenous administration of misonidazole to rats causes dose-limiting central nervous system toxicity without effects on peripheral nervous tissue. The lack of peripheral neurotoxicity was most likely due to a combination of several interrelated factors including route of administration, duration and intensity of the dosing regimen, and total cumulative dose.
Asunto(s)
Misonidazol/toxicidad , Enfermedades del Sistema Nervioso/inducido químicamente , Fármacos Sensibilizantes a Radiaciones/toxicidad , Animales , Conducta Animal/efectos de los fármacos , Encéfalo/patología , Ingestión de Alimentos/efectos de los fármacos , Glucuronidasa/metabolismo , Inyecciones Intravenosas , Masculino , Misonidazol/administración & dosificación , Actividad Motora/efectos de los fármacos , Enfermedades del Sistema Nervioso/patología , Enfermedades del Sistema Nervioso/psicología , Conducción Nerviosa/efectos de los fármacos , Fármacos Sensibilizantes a Radiaciones/administración & dosificación , Ratas , Ratas Sprague-Dawley , Aumento de Peso/efectos de los fármacosRESUMEN
Phenytoin is a hydantoin-type anticonvulsive agent used extensively for nearly sixty years in the prophylactic treatment of grand mal and psychomotor seizures. 2. Based upon somewhat contentious evidence of phenytoin-induced lymphoma in mice and upon epidemiologic evidence of an association between anticonvulsive therapy and lymphoma in epilepsy patients, the International Agency for Research on Cancer (IARC) has collectively regarded these data as limited evidence of carcinogenicity. 3. Two year carcinogenicity studies of standard bioassay design conducted in mice and rats yielded statistically significant increased incidence of hepatocellular adenomas in mice at phenytoin plasma concentrations approximating the therapeutic anticonvulsive range. Tumor incidence in rats was not affected. Previous carcinogenicity studies have found similar increases in hepatic tumor incidence in mice. 4. Phenytoin is a known enzyme inducer and shows tumor promoting activity in chemically initiated mouse liver. Evidence for genotoxicity is weak or equivocal, consequently phenytoin-induced liver tumors appear to occur through nongenotoxic mechanisms. 5. Finally, despite six decades of extensive therapeutic use and thorough epidemiologic evaluation, there is no evidence for an association between liver cancer and phenytoin therapy in epilepsy patients. Thus, hepatocellular neoplasia in phenytoin-treated rodents appears to be of little significance to man.
Asunto(s)
Anticonvulsivantes/toxicidad , Fenitoína/toxicidad , Animales , Anticonvulsivantes/efectos adversos , Anticonvulsivantes/sangre , Pruebas de Carcinogenicidad , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Neoplasias Hepáticas/inducido químicamente , Linfoma/epidemiología , Masculino , Ratones , Fenitoína/efectos adversos , Fenitoína/sangre , RatasRESUMEN
Induction of hepatic microsomal cytochrome P450 produced by carbamic acid [2,6-bis(1-methylethyl)phenoxy]sulfonyl]-2,6-bis(1-methylethyl) phenyl ester, monosodium salt (PD138142-15), a novel water-soluble inhibitor of acyl-CoA: cholesterol acyltransferase, was examined in male and female rats, dogs, and monkeys, and in male guinea pigs. Relative to control, PD138142-15 increased hepatic microsomal total spectral P450 in all species examined. Hepatic microsomal ethoxyresorufin-O-deethylase, pentoxyresorufin-O-dealkylase, and peroxisomal carnitine acetyltransferase activities and cyanide-insensitive Beta-oxidation were affected only marginally. Erythromycin-N-demethylase activity was increased (2- to 6-fold) in all three species in which it was examined (rat, dog and pig). Marked increases in immunoreactive P450 3A were noted in the rats and dogs, while slight increases were seen in monkeys. Pharmacokinetic studies of PD138142-15 in rats and dogs revealed pronounced decreases (80-90%) in plasma Cmax and AUC within 2 weeks of initiation of daily dosing. In spite of the marked decline in plasma drug levels, efficacy in dogs, as determined by serum cholesterol levels, was maintained for up to 6 weeks with continued dosing. Potential acid (gastric) breakdown products of PD 138142-15 were examined for their hepatic cytochrome P450 induction profiles in rats adn were found to differ both quantitatively and qualitatively from profiles produced by the parent compound. This suggested that induction observed in rats was due to parent PD138142-15 and not to any of the known potential acid breakdown products. The cumulative data establish that PD 138142-15 is an inducer of P450 3A in rats and dogs. The results also suggest that P450 3A is induced in monkeys and pigs as well, although the data are less definitive. Decreases in plasma drug levels imply that the compound may be an autoinducer in dogs and rats. The maintenance of efficacy in spite of decreased drugs levels in dogs suggests that the effects on serum cholesterol are due to a metabolite or that cholesterol lowering effects occur before the compound is metabolized by the liver.
Asunto(s)
Carbamatos/farmacología , Sistema Enzimático del Citocromo P-450/biosíntesis , Hipolipemiantes/farmacología , Microsomas Hepáticos/efectos de los fármacos , Animales , Carbamatos/farmacocinética , Colesterol/sangre , Perros , Inducción Enzimática , Femenino , Cobayas , Hipolipemiantes/farmacocinética , Macaca fascicularis , Masculino , Microsomas Hepáticos/enzimología , Ratas , Especificidad de la Especie , Esterol O-Aciltransferasa/antagonistas & inhibidoresRESUMEN
Angiotensin-converting enzyme inhibitors induce hypertrophy of renal juxtaglomerular cells in laboratory animals, and, in some studies, also produced renal tubular lesions. The objective of the present study was to evaluate the effects of the new angiotensin-converting enzyme inhibitor quinapril on renal function in normotensive rats. Male rats were dosed orally with quinapril at 0 (vehicle control) or 400 mg/kg for 1, 3, 8, 17 or 29 days. This dose of quinapril is more than 1000-fold greater than the effective antihypertensive dose in rats. Parameters of renal function were measured approximately 24 hours after dosing in order to minimize interference from acute pharmacologically mediated effects. Mean arterial blood pressure was only mildly affected at this time: 126.7 +/- 6.0 and 100.0 +/- 8.7 mm/Hg (mean +/- S.E.; day 29) for the control and quinapril-treated animals, respectively. Microscopic analysis of kidney tissue showed pronounced juxtaglomerular cell hypertrophy and hypergranularity in the quinapril-treated animals. These changes were first observed on day 7 and reached a maximum response by day 14. There were no morphologic changes in renal tubules. Quinapril had no significant effect on serum biochemistry parameters (electrolytes, urea nitrogen, creatinine). Urine output in quinapril-treated animals was increased 65% to 197% over controls during the course of the study and correlated with increased water consumption (r = 0.96). Urine osmolality was reduced 31% to 55% on days 8, 17 and 29. However, except for minimal reductions (< 15%) on day 8, there were no significant effects of quinapril on total (24 hour) urinary excretion of electrolytes or creatinine. There were also minimal effects of quinapril on direct measurements of renal function in anesthetized animals. Mean values (+/- S.E.) for control and quinapril-treated animals on day 29 were, respectively: glomerular filtration rate: 2.93 +/- 0.37 and 2.70 +/- 0.53 ml/min; effective renal plasma flow: 11.14 +/- 2.06 and 11.22 +/- 2.35 ml/min; effective renal tubular secretion: 267 +/- 63 and 261 +/- 106 micrograms/min; filtration fraction: 27.1 +/- 2.5 and 24.0 +/- 0.4%; and fractional sodium excretion: 0.25 +/- 0.04 and 0.34 +/- 0.04%. There were also no significant differences between control and quinapril-treated animals when the above parameters were measured following plasma volume expansion on day 29. The results show that quinapril had no adverse effects on renal function in rats when administered at a suprapharmacological dose for up to 4 weeks.(ABSTRACT TRUNCATED AT 400 WORDS)
Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Isoquinolinas/farmacología , Riñón/efectos de los fármacos , Tetrahidroisoquinolinas , Animales , Presión Sanguínea/efectos de los fármacos , Riñón/patología , Pruebas de Función Renal , Masculino , Volumen Plasmático/efectos de los fármacos , Quinapril , Ratas , Ratas WistarRESUMEN
This study supports the need to establish selection criteria that emphasize an individual's clinical experiences as part of the preceptor application process. This study further supports the need to provide a comprehensive workshop to prepare participants for the preceptor role.
Asunto(s)
Educación Continua en Enfermería/normas , Preceptoría , Rol , Cuidados Críticos , Humanos , Investigación en Educación de EnfermeríaAsunto(s)
Tumor de Células Granulares/veterinaria , Ratas Endogámicas , Enfermedades de los Roedores/patología , Neoplasias del Cuello Uterino/veterinaria , Neoplasias Vaginales/veterinaria , Animales , Femenino , Tumor de Células Granulares/patología , Tumor de Células Granulares/ultraestructura , Inmunohistoquímica , Microscopía Electrónica , Ratas , Neoplasias del Cuello Uterino/patología , Neoplasias del Cuello Uterino/ultraestructura , Neoplasias Vaginales/patología , Neoplasias Vaginales/ultraestructuraRESUMEN
Trimetrexate is a nonclassical folate antagonist that is active against a number of experimental murine and human tumor cell lines. To assess its toxicity, rats were administered single or repeated (daily x5) doses by either the oral or the intravenous route. Oral doses were 0, 90, 180, 295, and 375 mg/kg (single dose) and 0, 32, 65, and 80 mg/kg (daily x5). Intravenous doses were 0, 6, 20, and 60 mg/kg (single dose) and 0, 10, 20, and 30 mg/kg (daily x5). In the oral studies, signs of toxicity first appeared 2 to 3 days after initiation of dosing. Clinical signs included hypoactivity, diarrhea, urine scald, rhinorrhea, emaciation, and death. Significant pathologic findings were degenerative enteropathy in small and large intestines, bone marrow hypocellularity, decreased WBCs (neutrophils, lymphocytes), generalized lymphoid depletion, and testicular tubular degeneration. Except for the testicular changes, these effects were most severe in animals dosed at 65 and 80 mg/kg in the oral x5 study (65-70% mortality). Repeated oral doses at 32 mg/kg and single oral doses through 375 mg/kg caused only mild to moderate effects and less than 5% mortality. In contrast, single intravenous doses at 60 mg/kg resulted in immediate death (20% mortality) due to apparent CNS toxicity. Intravenous doses below 60 mg/kg were essentially asymptomatic. Toxicity in the intravenous studies was limited to decreased WBCs, splenic and thymic lymphoid depletion (repeated dosing), and testicular tubular degeneration and/or atrophy. Except for the testicular lesions, most of the effects in the oral and intravenous studies were reversible within 4 weeks. The results show that the acute toxicity of trimetrexate in rats is somewhat dependent on its route of administration, although the spectrum of effects is qualitatively similar to that observed in other species and with other folate antagonists. The dose-limiting toxicity of trimetrexate in rats common to both routes of administration is myelosuppression.
Asunto(s)
Trimetrexato/toxicidad , Administración Oral , Animales , Recuento de Células Sanguíneas , Peso Corporal/efectos de los fármacos , Médula Ósea/patología , Enfermedades de la Médula Ósea/inducido químicamente , Enfermedades de la Médula Ósea/patología , Ingestión de Alimentos/efectos de los fármacos , Femenino , Inyecciones Intravenosas , Masculino , Tamaño de los Órganos/efectos de los fármacos , Ratas , Ratas Endogámicas , Enfermedades Testiculares/inducido químicamente , Enfermedades Testiculares/patología , Trimetrexato/administración & dosificaciónRESUMEN
A granular cell variant of a cutaneous basal cell tumor in a Wistar rat is described. The tumor resembles the variant as described in man and dogs. The granular basal cells contain cytoplasmic PAS positive granules, and immunostained positively with HMW cytokeratins. Ultrastructurally, the cytoplasmic granules were secondary lysosomes.
Asunto(s)
Carcinoma Basocelular/patología , Neoplasias Cutáneas/patología , Animales , Carcinoma Basocelular/ultraestructura , Gránulos Citoplasmáticos/ultraestructura , Histocitoquímica , Técnicas para Inmunoenzimas , Masculino , Ratas , Ratas Wistar , Neoplasias Cutáneas/ultraestructura , Coloración y EtiquetadoRESUMEN
Metabolism of 1,2-dibromo-3-chloropropane (DBCP) was examined by direct 13C and 1H-13C correlated two-dimensional NMR spectroscopy of bile and urine of male albino rats treated intraperitoneally with [3-13C]DBCP at 81 mg/kg. The 3-13C label was introduced at 99% enrichment by coupling [13C]paraformaldehyde with vinyllithium to give [1-13C]allyl alcohol which was converted to allyl chloride with carbon tetrachloride/triphenylphosphine and then brominated. Fifteen 13C NMR signals were observed for biliary metabolites and twelve for urinary metabolites. Nine of the biliary metabolite 13C NMR signals were very similar or identical to those for nine urinary metabolites. The DBCP-derived moieties of five metabolites were identified by comparison of their 13C NMR chemical shifts, 13C multiplicities [obtained via the distortionless enhancement by polarization transfer (DEPT) pulse sequence], and chemical shifts of the directly-attached protons (obtained via two-dimensional NMR) with those of authentic standards. They were E- and Z-RSCH2CH = 13CHCl, RSCH2CHOH13CH2Cl, RSCH2CHOH13CH2OH and RS13CH2CHOHCH2OH, where R is probably glutathionyl in bile and N-acetylcysteinyl in urine. The mechanism proposed for formation of both the E- and Z-isomers of RSCH2CH = 13CHCl involves radical-initiated dehydrobromination followed by reaction of the intermediate allylic bromides with glutathione (GSH). The RSCH2CHOHCH2Cl conjugate may arise from direct GSH conjugation and hydrolysis of the secondary bromine via a thiiranium ion intermediate. The proposed origin of the RSCH2CHOHCH2OH conjugate labeled at either carbon-1 or carbon-3 is oxidation of DBCP at the bromomethyl or chloromethyl substituent, respectively, followed by two spontaneous dehydrohalogenations to give the highly reactive 2-bromopropenal, and addition of GSH followed by reduction of the aldehyde functionality. An alternative mechanism for the formation of the RSCH2CHOHCH2Cl and RSCH2CHOHCH2OH derivatives involves carbon-2 oxidation to give 1-bromo-3-chloroacetone followed by reaction with GSH and reduction of the ketone functionality with or without hydrolysis of the chloro substituent. 2-Bromopropenal, 1-bromo-3-chloroacetone, or GSH conjugates derived from these intermediates may be involved in the male reproductive toxicity, nephrotoxicity and genotoxicity of DBCP.
Asunto(s)
Propano/análogos & derivados , Animales , Bilis/metabolismo , Isótopos de Carbono , Glutatión/metabolismo , Espectroscopía de Resonancia Magnética , Masculino , Oxidación-Reducción , Propano/metabolismo , Propano/toxicidad , Ratas , Ratas EndogámicasRESUMEN
The mode of action of cantharidin, the natural vesicant of blister beetles, is examined by radioligand binding studies with mouse tissues. [3H]Cantharidin undergoes specific and saturable binding with the liver cytosol, which is characterized as follows: Kd and Bmax values of 30 nM and 1.8 pmol/mg of protein, respectively; linearity with respect to protein concentration; pH optimum of 6.5 to 7.5; association and dissociation half-times of 20 min and 12 hr, respectively; and 50% inhibition by Mg2+ at 70 microM, Ca2+ at 224 microM, pyrophosphate at 27 microM, and nucleotide triphosphates at 52-81 microM. The binding site undergoes a loss of activity at 45 degrees or higher. The toxicological relevance of this specific [3H]cantharidin binding site of mouse liver cytosol is established in three ways. First, the potency of 15 active cantharidin analogs for inhibiting [3H]cantharidin binding is correlated with their acute toxicity to mice (r = 0.829). Second, 26 related compounds that are inactive in inhibiting [3H]cantharidin binding are also of little or no toxicity to mice. Finally, the binding of [3H] cantharidin to liver cytosol from mice poisoned with increasing amounts of unlabeled cantharidin is inhibited in a dose-dependent manner. [3H]Cantharidin also specifically binds to cytosol fractions of blood, brain, heart, kidney, lung, pancreas, skin, spleen, and stomach. The characteristics of the specific binding site in brain are very similar to those determined in liver with respect to Kd, Bmax, association/dissociation kinetics, and sensitivity to inhibitors. It therefore appears that the toxicity of cantharidin and related oxabicycloheptanes, including the herbicide endothal, is attributable to binding at a specific site in liver and possibly other tissues.
Asunto(s)
Cantaridina/metabolismo , Animales , Sitios de Unión , Encéfalo/metabolismo , Cantaridina/toxicidad , Citosol/metabolismo , Cinética , Hígado/metabolismo , Masculino , Ratones , Conformación Proteica , Relación Estructura-Actividad , TritioRESUMEN
Cantharidin, the potent vesicant and toxicant of blister beetles, was prepared as a radioligand to probe its mechanism of action. [3H]Cantharidin interacts in a saturable and specific manner with a binding site in mouse liver cytosol with apparent Kd and Bmax values of 30 nM and 1.8 pmol/mg protein, respectively. Comparisons of cantharidic acid, the related herbicide endothal, and 20 other oxabicycloheptane-dicarboxylic acids show that their potency as inhibitors of [3H]cantharidin binding is closely correlated with their intraperitoneal toxicity to mice. This binding site is also inhibited in vivo by toxic doses of cantharidin. The [3H]cantharidin binding site in mouse liver cytosol therefore represents, or serves as a model for, the site of toxic action of cantharidin and structurally-related compounds.
Asunto(s)
Cantaridina/toxicidad , Hígado/metabolismo , Animales , Sitios de Unión , Cantaridina/análogos & derivados , Cantaridina/metabolismo , Fenómenos Químicos , Química , Citosol/metabolismo , Masculino , Ratones , Conformación Molecular , Relación Estructura-ActividadRESUMEN
Endothal and cantharidic acid were administered intraperitoneally to mice at 75 and 10 mg/kg, respectively, to compare their acute toxicity on liver tissue in vivo. Within 45 min both treatments caused extreme liver enlargement and congestion. Hepatic glycogenolysis was increased as evidenced by elevations in blood glucose and hepatic glycogen phosphorylase levels and by corresponding reductions in hepatic glycogen content and glycogen synthase activity. Endothal decreased hepatic ATP concentrations, although neither compound altered mitochondrial Mg2+-ATPase activity. Microsomal Mg2+-ATPase levels, however, were reduced by both treatments. There were no indications that reactive intermediates were involved in the toxicity of either compound. The results show that endothal and cantharidic acid act directly and cause similar biochemical changes in mouse liver in vivo.
Asunto(s)
Cantaridina/toxicidad , Ácidos Dicarboxílicos/toxicidad , Hígado/efectos de los fármacos , Animales , Glucemia , ATPasa de Ca(2+) y Mg(2+)/análisis , Glucógeno/metabolismo , Inyecciones Intraperitoneales , Hígado/enzimología , Masculino , RatonesRESUMEN
Young male C57BL mice were exposed nose-only to cigarette smoke 20 min/day for 8 weeks while maintained on diets containing 0, 5, and 100 ppm of vitamin E. Smoking had no effect on hepatic aryl hydrocarbon hydroxylase (AHH), UDP-glucuronyltransferase, glutathione S-transferase, parathion desulfurase, or parathion esterase activity. Lung AHH activity was increased in all smoke-exposed mice, although the increase was significantly less in animals maintained on the vitamin E-free diet. All mice on the vitamin E-free diet showed reduced lung AHH activity and increased hepatic lipid peroxidation. No other biotransformations tested were significantly altered by varying vitamin E concentrations alone or in combination with cigarette smoke. For all vitamin E diets, both the smoke-exposed and sham-treated mice gained significantly less weight than the control animals. This effect was attributed to stress induced by restraint of the animals within the smoking apparatus. The results of these experiments show that both cigarette smoke and vitamin E-deficient diets may affect xenobiotic metabolism but that the combination does not appear to alter markedly their individual effects or to induce ones not previously observed.